

# Liste der bewilligten Forschungsprojekte 2023

## Liste des projets de recherche acceptés en 2023

### Basic research

**Bastings Maartje** | Rewiring the spatial organisation of key checkpoint molecules to reverse the immuno-suppressive state of cancer

*Materials and Bioengineering, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne*

CHF 369 988 | 48 months | [KFS-5935-08-2023](#)

**Bentires-Alj Mohamed** | Effect of risk factors and preventive strategies on breast tumour dormancy

*Departement Biomedizin, Universitätsspital Basel, Basel*

CHF 375 000 | 36 months | [KFS-5765-02-2023](#)

**Brisken Cathrin** | The role of androgen receptor signalling in the human breast epithelium: can anti-androgenic progestins prevent breast cancer?

*SV ISREC UPBRI, EPF de Lausanne, Lausanne*

CHF 369 800 | 36 months | [KFS-5771-02-2023](#)

**Cafilisch Amedeo** | Targeting the m6A-RNA epitranscriptomic mark as a novel therapy for blood cancer

*Biochemistry, University of Zurich, Zürich*

CHF 374 800 | 36 months | [KFS-5748-02-2023](#)

**Cavalli Andrea** | Discovery and optimization of WWP1 inhibitors as new anti-prostate-cancer drugs

*Computational Structural Biology, Institute for Research in Biomedicine (IRB), Bellinzona*

CHF 208 250 | 36 months | [KFS-5777-02-2023](#)

**Modena Mario Matteo** | Bidirectional interactions of glioma and neural cells: investigating glioma cells integration into brain networks and modulation of brain activity

*Biosystems Science and Engineering, ETH Zürich, Basel*

CHF 301 988 | 48 months | [KFS-5959-08-2023](#)

**Münz Christian** | Targeting the human oncogenic Kaposi sarcoma associate herpesvirus (KSHV) via its gene products and specific T cell responses

*Institut für Experimentelle Immunologie, Universität Zürich (UZH), Zürich*

CHF 375 000 | 36 months | [KFS-5896-08-2023](#)

**Platt Randall** | Systematic functional interrogation of clinical variants of uncertain significance using precision gene editing

*Department of Biosystems Science and Engineering, ETH Zürich, Basel*

CHF 375 000 | 36 months | [KFS-5736-02-2023](#)

**Scheiermann Christoph** | Circadian dynamics in tumour infiltrating leukocyte (TIL) fate and phenotype

*Département de Pathologie et Immunologie, Université de Genève (UNIGE), Genève*

CHF 374 997 | 36 months | [KFS-5898-08-2023](#)

**Sendoel Ataman** | Single-cell CRISPR to characterize small open reading frames in cancer

*Institute for Regenerative Medicine, University of Zurich, Schlieren-Zurich*

CHF 250 000 | 24 months | [KFS-5730-02-2023](#)

**Standfuss Joerg** | A molecular view of melanoma-associated BRAF kinase dynamics

*Laboratory of Biomolecular Research, Paul Scherrer Institut (PSI), Villigen PSI*

CHF 371 600 | 48 months | [KFS-5737-02-2023](#)

**Thomä Nicolas** | Tuning nuclear receptor activation & degradation for therapeutic benefit in cancer

*Genome Regulation, Friedrich Miescher Institut für biomedizinische Forschung (FMI), Basel*

CHF 374 990 | 36 months | [KFS-5933-08-2023](#)

**Trono Didier** | Targeting the human-restricted oncogene POU5F1B for precision oncology

*Global Health Institute, EPF de Lausanne, Lausanne*

CHF 374 500 | 36 months | [KFS-5823-02-2023](#)

**Vallelian Florence** | Haemorrhage-induced NRF2 signalling in tumour-associated macrophages drives cancer growth, invasion, and immunotherapy resistance

*Internal medicine, University Hospital Zurich, Zurich*

CHF 374 750 | 36 months | [KFS-5944-08-2023](#)

**Verdeil Gregory** | Mechanisms regulating NFAT5 dependent inhibition of anti-tumour response in exhausted CD8 T-cells

*Oncologie fondamentale, Université de Lausanne (UNIL), Epalinges*

CHF 370 100 | 36 months | [KFS-5770-02-2023](#)

**von Gunten Stephan** | PILRalpha glyco-immune checkpoints in cancer

*Institut für Pharmakologie, Universität Bern, Bern*

CHF 375 000 | 36 months | [KFS-5936-08-2023](#)

**Vozenin Marie-Catherine** | Understanding how FLASH radiotherapy works: investigating the transcriptional and Wnt dependency of FLASH in zebrafish embryo

*Service de Radio-Oncologie, Hôpitaux universitaires de Genève (HUG), Geneva*

CHF 366 600 | 36 months | [KFS-5757-02-2023](#)

## Epidemiological research

**Krieger Jean-Philippe** | Do vagal inputs to the stomach promote gastric cancer incidence in humans? A nationwide cohort study to bridge the gap between preclinical studies and therapeutic applications

*Institute of Veterinary Pharmacology and Toxicology, University of Zurich, Zurich*

CHF 196 350 | 36 months | [KFS-5745-02-2023](#)

**Rohrman Sabine** | Impact of COVID-19 pandemic on cancer diagnosis and case stage distribution in the cantons of Zurich and Zug

*Abteilung Epidemiologie Chronischer Krankheiten, Institut für Epidemiologie, Biostatistik und Prävention (EBPI), Zürich*

CHF 117 900 | 24 months | [KFS-5731-02-2023](#)

## Clinical Research – laboratory-oriented

**Fix Michael** | Unlocking new frontiers in radiotherapy: treatment planning for very high-energy electron therapy

*Division of Medical Radiation Physics and Department of Radiation Oncology, Inselspital Bern, Bern*

CHF 239 041 | 24 months | [KFS-5948-08-2023](#)

**Hartmann Karin** | Investigation of the immune milieu in mastocytosis to explore novel treatment options

*Department of Biomedicine, University Hospital Basel, Basel*

CHF 357 318 | 36 months | [KFS-5979-08-2023](#)

**Le Magnen Clementine** | Investigating the role of glucocorticoid receptor signalling in cellular plasticity and bladder cancer progression

*Department of Biomedicine, Institute of Pathology, and Department of Urology, University Hospital Basel, Basel*

CHF 317 627 | 48 months | [KFS-5996-08-2023](#)

**Levesque Mitchell** | Multi-modal single cell analysis of primary and metastatic uveal melanoma

*Dermatology, University of Zurich, Schlieren*

CHF 370 500 | 42 months | [KFS-5785-02-2023](#)

**McKee Thomas** | Genomic and clinical characterization of responders to PARP inhibitors in ovarian cancer

*Service de Pathologie Clinique, Hôpitaux universitaires de Genève (HUG), Genève*

CHF 304 395 | 36 months | [KFS-5977-08-2023](#)

**Rubin Mark A.** | Towards a novel theranostics approach for AR-negative castration-resistant prostate cancer

*Department for BioMedical Research (DBMR), Universität Bern, Bern*

CHF 343 650 | 36 months | [KFS-5754-02-2023](#)

**Weiss Tobias** | Spatially resolved functional drug & immunotherapy profiling for novel combination therapies against glioblastoma

*Department of Neurology, University Hospital Zurich, Zurich*

CHF 291 450 | 36 months | [KFS-5763-02-2023](#)

**Zucca Emanuele** | IELSG52: integrated molecular and clinical profiling to improve disease characterization and outcome prediction in nodal marginal zone lymphoma

*IELSG, Institute of Oncology Research (IOR), Bellinzona*

CHF 306 400 | 48 months | [KFS-5778-02-2023](#)

## Clinical Research – patient-oriented

**Chalandon Yves** | A 3-cohort randomized study evaluating the place of new immunotherapeutic agents in frontline therapy of adult patients with acute lymphoblastic leukaemia (ALL) and the role of allogeneic haematopoietic stem cell transplantation (HSCT) in the phpos subgro

*Service d'hématologie, Hôpitaux universitaires de Genève (HUG), Genève 14*

CHF 371 600 | 48 months | [KFS-5807-02-2023](#)

**Fierstra Jorn** | A creative hypoxia-targeted fMRI approach for contrast free perfusion and tumour hypoxia measurements in patients with glioblastoma

*Neurosurgery, University Hospital Zurich, Zürich*

CHF 350 443 | 36 months | [KFS-5983-08-2023](#)

**Hutter Gregor** | First in human clinical trial with armoured anti-EGFRvIII-SGRP CARs against glioblastoma

*Neurochirurgische Klinik, Universitätsspital Basel, Basel*

CHF 375 000 | 48 months | [KFS-5789-02-2023](#)

**Rentsch Cyrill A.** | DISSECTION 2.0 - extended pelvic lymphadenectomy (ePLND) versus no ePLND during radical prostatectomy in high-risk, localized prostate cancer: a prospective randomized phase III study

*Abteilung Urologie, Universitätsspital Basel, Basel*

CHF 374 650 | 48 months | [KFS-5775-02-2023](#)

**Riesterer Oliver** | Analysis of clinical outcomes and modelling of the interaction between hyperthermia and radio(chemo)therapy in cancer patients

*Radio-Onkologie-Zentrum KSA-KSB, Kantonsspital Aarau AG, Aarau*

CHF 239 450 | 24 months | [KFS-5746-02-2023](#)

**Todic Jelena** | The robotic-assisted extended "Sistrunk" approach (RESA) for tumours of the upper aerodigestive tract with limited transoral access: a new surgical technique to improve laryngo-esophageal dysfunction free survival (LDFS)

*Surgery, Central University Hospital of Vaud (CHUV), Lausanne*

CHF 365 786 | 48 months | [KFS-5920-08-2023](#)

**Wiest Reiner** | Safety of biliary intraductal radiofrequency ablation in patients with unresectable extrahepatic biliary tract cancer (EBTC) undergoing standard of care chemotherapy: ABLATIO-BILICA

*Universitätsklinik für Viszerale Chirurgie und Medizin (UVCM), Inselspital Bern, Bern*

CHF 332 300 | 36 months | [KFS-5812-02-2023](#)

**Zlobec Inti** | Response prediction using spatial analysis of the dynamic tumour microenvironment following neoadjuvant treatment in localized rectal cancer

*Institut für Pathologie, University of Bern, Bern*

CHF 371 950 | 36 months | [KFS-5786-02-2023](#)

## Health services research

**Selby Kevin** | Lausanne lung cancer screening pilot program

*Département des Policliniques, Unisanté - Centre universitaire de médecine générale et santé publique - Lausanne, Lausanne*

CHF 77 400 | 12 months | [KFS-5909-08-2023](#)

## Psychosocial research

**Chevallay Mickael** | Assessing medical professionals and cancer patients' preferences for quality of life (QoL) and length of life (LoL) in oncology: a study on gastric and esophageal cancer

*Chirurgie viscérale, Hôpitaux universitaires de Genève (HUG), Genève*

CHF 225 870 | 36 months | [KFS-5986-08-2023](#)

**Schwappach David** | Psychological harm as patient safety concern in advanced cancer care

*Institute of Social and Preventive Medicine, Universität Bern, Bern*

CHF 368 900 | 35 months | [KFS-5738-02-2023](#)

**Waespe Nicolas** | Improving cancer predisposition syndrome detection: a patient-centric approach

*Pediatric Hematology/ Oncology, Inselspital Bern, Bern*

CHF 327 364 | 36 months | [KFS-5992-08-2023](#)

**Witt Claudia** | eLearning of self-acupressure or a mindfulness technique to support symptom management in people with cancer: randomized controlled trials

*Institute for Complementary and Integrative Medicine, University Hospital Zurich, Zürich*

CHF 372 400 | 36 months | [KFS-5723-02-2023](#)

## Fellowships

**Bilfeld Gilles Maxime** | Exploiting circulating tumour cells for the identification of immunotherapy responders

*Department of Biology, ETH Zürich, Langnau am Albis*

CHF 196 341 | 38 months | [MD-PhD-5892-06-2023](#)

**Bürgin Damian Timo** | The functional role of CD93 in multiple myeloma

*Department of Biomedical Research, University of Bern, Bern*

CHF 190 851 | 36 months | [MD-PhD-5891-06-2023](#)

**Russkamp Norman Frederik** | Development of TRAC-controlled HSPC-derived CAR T-cells for the treatment of haematological malignancies

*Department of Hematology, Universitätsspital Basel, Zürich*

CHF 126 000 | 24 months | [KFS-5799-02-2023](#)

Im [Forschungsportal](#) finden Sie Informationen zu allen Projekten, die die Stiftung Krebsforschung Schweiz und ihre Partnerorganisation Krebsliga Schweiz seit dem Jahr 2005 gefördert haben.

*Dans le [portail de recherche](#), vous trouverez les informations sur tous les projets soutenus par la fondation Recherche suisse contre le cancer et son organisation partenaire, la Ligue suisse contre le cancer, depuis 2005.*